POCARED Diagnostics

Company Overview

Snapshot

Founded in July 2004 by Jonathan Gurfinkel and Gal Ingber, POCARED Diagnostics operates with 1–10 employees. The company has raised a total of $103.38 million across 5 funding rounds from 6 investors. In May 2022, the European Investment Bank (EIB) provided backing for the completion of development and commercialization of its rapid testing system.

Business overview

POCARED Diagnostics is an in vitro diagnostics company specializing in the development of a microbiology platform. Its core product, the P-1000, is an automated rapid system that utilizes intrinsic fluorescence, optical data analysis, and artificial intelligence to analyze the multidimensional optical characteristics of microorganisms for pathogen detection. Additionally, the company offers the SP system, a highly efficient, general-use, rapid-filtration-based fractionation concentration platform designed for high rates of cell recovery and viability. POCARED Diagnostics operates in the Health Tech & Life Sciences sector, serving markets such as laboratories and hospitals with its medical technologies for infectious disease diagnostics.

Strategic signal

POCARED Diagnostics secured a significant backing from the European Investment Bank (EIB) in May 2022, aimed at accelerating the development and commercialization of its rapid infectious diseases testing system. This investment signals strong institutional confidence in the company's technology and its potential to address critical needs in rapid diagnostics, positioning POCARED for advanced market entry and broader adoption of its microbiology platform.

Company Intelligence Q&A

What is the primary focus of POCARED Diagnostics?

POCARED Diagnostics focuses on developing an in vitro diagnostics microbiology platform, including the P-1000 automated rapid system for microorganism detection and the SP system for biological particle concentration.

When did POCARED Diagnostics cease operations?

POCARED Diagnostics ceased to operate in February 2025.

What was a significant funding event for POCARED Diagnostics in 2022?

In May 2022, POCARED Diagnostics secured backing from the European Investment Bank (EIB) to complete the development and commercialization of its rapid testing system.

What was the nature of the capital commitment POCARED Diagnostics received in July 2021?

In July 2021, POCARED Diagnostics secured a $50 million capital commitment from Global Emerging Markets Group (GEM) as the company explored going public via a SPAC merger.

Which investors participated in POCARED Diagnostics' funding round in March 2014?

In March 2014, POCARED Diagnostics received funding from RDC and Elron Ventures.